AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Target
Upside 486%
Price (€) 1.95
Market Cap (€M) 71.2
Perf. 1W: -12.9%
Perf. 1M: -42.4%
Perf. 3M: -65.2%
Perf Ytd: -60.8%
10 day relative perf. to stoxx600: -36.8%
20 day relative perf. to stoxx600: -41.1%
EPS change27/03/2023

No real news in the FY22 results.

Change in EPS2023 : € -0.23 vs -0.33ns
2024 : € 0.49 vs 0.41+20.8%

We have updated our model after the release of the FY22 results. The latter were not meaningful (as usual) since the investment case is based on future product launches (hopefully as of FY24). Concerning our short-term earnings forecasts, they have been fine-tuned to factor in a slightly-higher contribution to revenues from the BARDA agreement signed last June. This is not a game changer in the short-term, but will still provide the group with an extra financing source in the current year and next.



Updates

03 Apr 24 Earnings/sales releases
Patience is a virtue… hopefully

28 Feb 24 Financing issue
Securing the financing needs

08 Feb 24 Strategic Plan
No news is not always good news...

03 Jan 24 Other news/comments
A new distribution agreement in Northern Europe

27 Mar 23 EPS change
No real news in the FY22 results.

23 Mar 23 Earnings/sales releases
FY22: not much to learn from the release

26 Sep 22 EPS change
Minor changes after H1 22

.